Blair William & Co. IL cut its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 42.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 141,287 shares of the medical equipment provider's stock after selling 106,111 shares during the quarter. Blair William & Co. IL owned approximately 0.06% of Hologic worth $10,185,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Brooklyn Investment Group raised its holdings in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after purchasing an additional 145 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC lifted its holdings in Hologic by 2.1% during the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock worth $602,000 after buying an additional 169 shares during the period. UMB Bank n.a. lifted its holdings in Hologic by 4.1% during the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock worth $343,000 after buying an additional 188 shares during the period. Finally, Private Trust Co. NA boosted its position in Hologic by 19.6% during the 3rd quarter. Private Trust Co. NA now owns 1,166 shares of the medical equipment provider's stock valued at $95,000 after acquiring an additional 191 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the company. Royal Bank of Canada decreased their price objective on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research note on Thursday, February 6th. Stephens reiterated an "overweight" rating and issued a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Leerink Partners cut shares of Hologic from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Jefferies Financial Group initiated coverage on shares of Hologic in a research report on Tuesday, December 10th. They issued a "hold" rating and a $85.00 price objective on the stock. Finally, Evercore ISI decreased their target price on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Hologic presently has an average rating of "Hold" and an average price target of $84.62.
Read Our Latest Report on Hologic
Hologic Stock Performance
HOLX traded down $0.32 on Thursday, reaching $60.24. 472,263 shares of the stock were exchanged, compared to its average volume of 1,805,806. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company's 50-day moving average price is $64.69 and its 200 day moving average price is $72.88. The firm has a market capitalization of $13.52 billion, a PE ratio of 19.00, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a fifty-two week low of $58.38 and a fifty-two week high of $84.67.
Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.
About Hologic
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Read More
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
